Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

Phase 1/2 Terminated 43 enrolled Pfizer

Non-randomizedParallel-groupOpen-labelTreatment

The purpose of this study is to evaluate the safety and efficacy of avelumab when combined with either crizotinib or PF-06463922.

Evaluation	Drug	Modality	Dose	Route
Subject	Avelumab	Monoclonal antibody	5 mg/kg	Intravenous
Subject	Avelumab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Crizotinib	Small molecule	200 mg	Oral
Subject	Crizotinib	Small molecule	250 mg	Oral
Subject	Lorlatinib	Small molecule	50 mg	Oral
Subject	Lorlatinib	Small molecule	75 mg	Oral
Subject	Lorlatinib	Small molecule	100 mg	Oral